350 related articles for article (PubMed ID: 18381930)
1. Endoglin (CD105): a marker of tumor vasculature and potential target for therapy.
Dallas NA; Samuel S; Xia L; Fan F; Gray MJ; Lim SJ; Ellis LM
Clin Cancer Res; 2008 Apr; 14(7):1931-7. PubMed ID: 18381930
[TBL] [Abstract][Full Text] [Related]
2. Endoglin: An accessory component of the TGF-beta-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies.
Fonsatti E; Del Vecchio L; Altomonte M; Sigalotti L; Nicotra MR; Coral S; Natali PG; Maio M
J Cell Physiol; 2001 Jul; 188(1):1-7. PubMed ID: 11382917
[TBL] [Abstract][Full Text] [Related]
3. Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels.
Fonsatti E; Altomonte M; Nicotra MR; Natali PG; Maio M
Oncogene; 2003 Sep; 22(42):6557-63. PubMed ID: 14528280
[TBL] [Abstract][Full Text] [Related]
4. Endoglin (CD105): a review of its role in angiogenesis and tumor diagnosis, progression and therapy.
Nassiri F; Cusimano MD; Scheithauer BW; Rotondo F; Fazio A; Yousef GM; Syro LV; Kovacs K; Lloyd RV
Anticancer Res; 2011 Jun; 31(6):2283-90. PubMed ID: 21737653
[TBL] [Abstract][Full Text] [Related]
5. Endoglin-mediated vascular remodeling: mechanisms underlying hereditary hemorrhagic telangiectasia.
Lebrin F; Mummery CL
Trends Cardiovasc Med; 2008 Jan; 18(1):25-32. PubMed ID: 18206806
[TBL] [Abstract][Full Text] [Related]
6. Organ-specific endoglin (CD105) expression in the angiogenesis of human cancers.
Minhajat R; Mori D; Yamasaki F; Sugita Y; Satoh T; Tokunaga O
Pathol Int; 2006 Dec; 56(12):717-23. PubMed ID: 17096728
[TBL] [Abstract][Full Text] [Related]
7. CD105 is important for angiogenesis: evidence and potential applications.
Duff SE; Li C; Garland JM; Kumar S
FASEB J; 2003 Jun; 17(9):984-92. PubMed ID: 12773481
[TBL] [Abstract][Full Text] [Related]
8. Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer.
Wikström P; Lissbrant IF; Stattin P; Egevad L; Bergh A
Prostate; 2002 Jun; 51(4):268-75. PubMed ID: 11987155
[TBL] [Abstract][Full Text] [Related]
9. [Endoglin (CD105)--a target for visualization and anti-angiogenic therapy for malignant tumors].
Smirnov IV; Gryazeva IV; Samoilovich MP; Klimovich VB
Vopr Onkol; 2015; 61(6):898-907. PubMed ID: 26995976
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide.
Takahashi N; Haba A; Matsuno F; Seon BK
Cancer Res; 2001 Nov; 61(21):7846-54. PubMed ID: 11691802
[TBL] [Abstract][Full Text] [Related]
11. Endoglin in angiogenesis and vascular diseases.
ten Dijke P; Goumans MJ; Pardali E
Angiogenesis; 2008; 11(1):79-89. PubMed ID: 18283546
[TBL] [Abstract][Full Text] [Related]
12. Specific expression of endoglin (CD105) in endothelial cells of intratumoral blood and lymphatic vessels in pancreatic cancer.
Yoshitomi H; Kobayashi S; Ohtsuka M; Kimura F; Shimizu H; Yoshidome H; Miyazaki M
Pancreas; 2008 Oct; 37(3):275-81. PubMed ID: 18815549
[TBL] [Abstract][Full Text] [Related]
13. Immunocytochemical detection of endoglin is indicative of angiogenesis in malignant melanoma.
Bodey B; Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1998; 18(4A):2701-10. PubMed ID: 9703932
[TBL] [Abstract][Full Text] [Related]
14. Endoglin (CD105) expression in angiogenesis of colon cancer: analysis using tissue microarrays and comparison with other endothelial markers.
Minhajat R; Mori D; Yamasaki F; Sugita Y; Satoh T; Tokunaga O
Virchows Arch; 2006 Feb; 448(2):127-34. PubMed ID: 16177881
[TBL] [Abstract][Full Text] [Related]
15. CD105 prevents apoptosis in hypoxic endothelial cells.
Li C; Issa R; Kumar P; Hampson IN; Lopez-Novoa JM; Bernabeu C; Kumar S
J Cell Sci; 2003 Jul; 116(Pt 13):2677-85. PubMed ID: 12746487
[TBL] [Abstract][Full Text] [Related]
16. [The immunohistochemical expression of CD105 is a marker for high metastatic risk and worse prognosis in breast cancers].
Charpin-Taranger C; Dales JP; Garcia S; Andrac-Meyer L; Ramuz O; Carpentier-Meunier S; Bonnier P
Bull Acad Natl Med; 2003; 187(6):1129-45; discussion 1145-6. PubMed ID: 14978873
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical evaluation of the microvascular density through the expression of TGF-beta (CD 105/endoglin) and CD 34 receptors and expression of the vascular endothelial growth factor (VEGF) in oligodendrogliomas.
Netto GC; Bleil CB; Hilbig A; Coutinho LM
Neuropathology; 2008 Feb; 28(1):17-23. PubMed ID: 18181830
[TBL] [Abstract][Full Text] [Related]
18. Emerging roles of endoglin/CD105 and angiogenic cytokines for disease development and progression in multiple myeloma patients.
Pappa CA; Alexandrakis MG; Boula A; Psarakis FE; Kolovou A; Bantouna V; Stavroulaki E; Tsirakis G
Hematol Oncol; 2013 Dec; 31(4):201-5. PubMed ID: 23576184
[TBL] [Abstract][Full Text] [Related]
19. Emerging role of endoglin (CD105) as a marker of angiogenesis with clinical potential in human malignancies.
Fonsatti E; Sigalotti L; Arslan P; Altomonte M; Maio M
Curr Cancer Drug Targets; 2003 Dec; 3(6):427-32. PubMed ID: 14683500
[TBL] [Abstract][Full Text] [Related]
20. Over-expression of endoglin (CD105): a marker of breast carcinoma-induced neo-vascularization.
Bodey B; Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1998; 18(5A):3621-8. PubMed ID: 9858949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
